SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors

Neuroendocrine Tumors Clinical Trial

Official title:

Correlation Between SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02840149
• Other study ID #: CODIM-MDM-16-211
• Status: Completed
• Phase: Phase 3
• Start date: October 1, 2019
• Est. completion date: December 13, 2023

Study information

• Verified date: December 2023
• Source: Jewish General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Positron emission tomography/computed tomography (PET/CT) is an advanced nuclear medicine scan. This technology allows precise and early cancer to be visualized and measured on whole body images. Patients with Neuro-Endocrine tumors (NETs), require specialized molecular imaging to stage, re-stage and assess eligibility and response to therapy. 68Ga-DOTATATE is a nuclear medicine imaging agent that is not yet approved by Health Canada but used extensively throughout the world. The Ki-67 index, a marker of cell proliferation in NETs, is one of the most important prognostic factors in this disease. The objective of this study is to evaluate if the maximal standard uptake value (SUVmax) on PET/CT in NETs inversely correlates with Ki-67 score on initial biopsy. If this hypothesized correlation between SUV and Ki-67 score is reproduced, then DOTATATE would serve as a non-invasive method to assess cellular proliferation and therefore prognosis of these patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 45
• Est. completion date: December 13, 2023
• Est. primary completion date: December 13, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Known or suspected somatostatin receptor positive tumor such as: neuroendocrine tumor (carcinoid, gastro-entero-pancreatic neuroendocrine tumors, etc); pheochromocytoma; neuroblastoma; medulloblastoma; ectopic Cushing syndrome/non-pituitary ACTH elevation; tumor-induced osteomalacia. Supporting evidence may include MRI, CT, biochemical markers, and/or pathology report.

• Previous diagnosis of NET with Ki-67 index available or soon to be obtained.

• ECOG performance status 0 - 3, inclusive.

• 18 years or older and able to understand and provide written informed consent

• Patients must be able to tolerate the physical/logistical requirements of a PET/CT scan including lying supine for up to 45 minutes with the arms above the head and tolerating intravenous cannulation for injection of the study drug

Exclusion Criteria:

• Medically unstable patients (e.g. acute cardiac or respiratory distress or hypotensive, etc.)

• Patients who exceed the safe weight limit or bore of the PET/CT bed

• Patients who are claustrophobic or pregnant

Related Conditions & MeSH terms

• Endocrine Gland Neoplasms
• Neuroendocrine Tumors

Intervention

Drug:
• 68Ga-DOTATATE PET/CT
68Ga-DOTATATE PET/CT scan

Locations

Country	Name	City	State
Canada	Jewish General Hospital	Montréal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Jewish General Hospital

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlation between SUV on 68Ga-DOTATATE PET/CT with Ki-67 index in NET	To determine whether there is an inverse correlation between SUV on 68Ga-DOTATATE PET/CT with Ki-67 index in patients with neuroendocrine tumors	2 years